Tyme Technologies, Inc. announced that Mack Roach III, M.D., FASTRO, FACR, Professor of Radiation Oncology, Medical Oncology and Urology at the University of California, San Francisco (UCSF), will lead one or more investigator-initiated trials to evaluate SM-88 therapy in prostate cancer. As part of the collaboration, Tyme will provide support to Dr. Roach to conduct a randomized, investigator-sponsored trial comparing active surveillance (AS) to SM-88 maintenance therapy in patients prior to definitive therapy. In addition, the collaboration will evaluate trials in select patient populations after relapsing from definitive therapy. These trials will be conducted at UCSF and potentially expand to other academic sites.